Coloplast A/ S stock (DK0060448595): Q3 update keeps focus on US growth and chronic care demand

Coloplast A/S has reported results for Q3 2024/25 and highlighted continued demand in ostomy and continence care, while keeping its eyes on US market growth and innovation. What drives the Danish medtech group’s business model – and what matters for stock-focused investors?

Coloplast A/S, the Danish medical device group focused on chronic care, recently reported financial results for the third quarter of its 2024/25 financial year, providing fresh insights into demand trends in ostomy care, continence care and advanced wound care, according to a quarterly update published on the company’s investor relations site in August 2025 and summarized by InvestorPlace on August 20, 2025 (Coloplast investor relations as of 08/20/2025; InvestorPlace as of 08/20/2025).

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Coloplast
• Sector/industry: Medical devices, chronic care
• Headquarters/country: Humlebaek, Denmark
• Core markets: Europe, North America, selected growth markets
• Key revenue drivers: Ostomy care, continence care, advanced wound care
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: COLO B)
• Trading currency: Danish krone (DKK)

Coloplast A/S: core business model

Coloplast A/S develops and markets medical devices for people living with chronic conditions, particularly those requiring ostomy care, continence care, and advanced wound and skin care. The company’s products are typically reimbursed by public health systems or private insurers, making reimbursement frameworks and tender dynamics key external factors for its business model, as described in its annual report for the 2023/24 financial year published in November 2024 (Coloplast annual report as of 11/20/2024).

In ostomy care, Coloplast offers pouches, baseplates, accessories and related solutions for patients after surgical procedures that route bodily waste through a stoma. These products must combine skin-friendliness, leakage protection and discretion in everyday life. The company’s ostomy portfolio is one of its largest revenue contributors and spans offerings such as one-piece and two-piece systems, convex baseplates and specialized adhesive technologies, according to its product overview in 2024 (Coloplast product overview as of 10/15/2024).

The continence care segment serves patients with bladder and bowel dysfunction. Coloplast provides intermittent catheters, urinary bags and male external catheters designed to reduce infection risk and improve comfort. Many of these products are single?use and are ordered regularly, which can generate recurring revenue streams over the lifetime of a patient, subject to prescription and reimbursement conditions, as outlined in the company’s 2023/24 annual report (Coloplast annual report as of 11/20/2024).

Advanced wound and skin care is another pillar. Here Coloplast markets dressings, foams, and other wound management solutions for chronic wounds such as diabetic foot ulcers, venous leg ulcers and pressure ulcers. Demand is driven by aging populations, the prevalence of diabetes and the need to prevent complications that can lead to hospitalization or amputation. Industry research from 2024 estimated the global active wound care market at several billion US dollars with mid?single?digit annual growth, mentioning Coloplast among the established suppliers (OpenPR market report as of 03/12/2024).

Across these segments, Coloplast’s business model relies heavily on close collaboration with healthcare professionals, including nurses and hospital procurement departments. The company provides product training, patient support programs and clinical documentation to underpin the use of its devices in daily practice. This service component is intended to strengthen customer relationships and support tender success, especially in hospital-driven markets in Europe and in the United States, as described in investor presentations during 2024 (Coloplast investor presentation as of 12/05/2024).

Main revenue and product drivers for Coloplast A/S

According to Coloplast’s 2023/24 annual report, ostomy care and continence care are the largest contributors to group revenue, followed by advanced wound and skin care and smaller businesses such as interventional urology. The company reported that chronic conditions requiring colostomy, ileostomy or urostomy care form a stable, growing patient base, with product usage tied to everyday routines, as highlighted in the report released in November 2024 (Coloplast annual report as of 11/20/2024).

In ostomy care, new product generations with improved adhesives, flexible baseplates and discrete pouch designs are an important growth driver. Innovations that can reduce skin complications or offer longer wear time may support premium pricing and foster patient loyalty, which in turn can be relevant for long-term prescription patterns in markets like the US and Germany. Coloplast has repeatedly emphasized the role of innovation and product launches in sustaining above-market growth in its key segments, including during capital markets communications in 2024 (Coloplast capital markets update as of 12/05/2024).

In continence care, recurring demand for intermittent catheters and urine collection systems is crucial. The company’s portfolio includes hydrophilic-coated catheters designed to ease insertion and reduce friction. Reimbursement rules can determine whether patients in a specific healthcare system receive higher-end catheters or more basic products. Consequently, policy changes or tender outcomes in large markets, such as US Medicare-related segments or German sickness funds, can influence segment revenue trends, as discussed in the 2023/24 annual report (Coloplast annual report as of 11/20/2024).

Advanced wound care demand is closely linked to demographic and lifestyle factors. As the prevalence of diabetes and vascular disease increases worldwide, more patients are at risk of chronic wounds, creating a steady need for dressings and related solutions. Market research in March 2024 projected that the active wound care market could reach around USD 3.91 billion over the coming years, with established suppliers like Coloplast positioned to participate in that growth, according to an analysis summarized by Mordor Intelligence and shared via OpenPR (OpenPR / Mordor Intelligence as of 03/12/2024).

Beyond individual product lines, Coloplast’s regional mix also drives revenue. Europe remains a core region, but the company has highlighted North America, particularly the United States, as a strategic growth market. In the US, Coloplast seeks to gain share in both ostomy and continence care by expanding its sales force, strengthening relationships with payers and distributors, and tailoring its product and marketing strategies to local reimbursement frameworks, as indicated in its 2024 investor presentations (Coloplast investor presentation as of 12/05/2024).

From a financial perspective, Coloplast has traditionally emphasized profitability and cash generation, supporting dividend payments to shareholders. While exact figures can fluctuate from year to year, the company reported solid margins and free cash flow in its 2023/24 results, which management framed as enabling continued investment in R&D and selective acquisitions in chronic care niches, according to the annual report published in November 2024 (Coloplast annual report as of 11/20/2024).

Conclusion

Coloplast A/S operates with a focused business model centered on chronic care, generating recurring revenue from ostomy, continence and advanced wound care products. Recent quarterly and annual reporting has underscored stable demand drivers, particularly demographic trends and the ongoing need for specialized medical devices. At the same time, the company’s growth ambitions, especially in the United States, depend on execution in competitive tenders, reimbursement environments and innovation cycles. For stock-focused readers, Coloplast’s combination of mature European exposure and targeted US expansion presents a profile shaped by defensive healthcare demand and regulatory and pricing dynamics. As with any equity, the balance of opportunities and risks, including policy changes, competitive pressures and currency moves, plays a key role in how the stock may be perceived in diversified portfolios.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.